New Research Supports Continuing ADHD Medication During Pregnancy for Many Women
Last updated:
If you’ve ever watched a pregnant woman grapple with the impossible-seeming choice between managing her focus needs and worrying about her baby’s health, you know how isolating that decision can feel. The fear of judgment—from doctors, from family, from herself—can be overwhelming. That instinct to seek clear guidance is completely valid. Emerging research presented at a major psychiatric conference suggests that for many women, continuing ADHD medication during pregnancy may be a reasonable and safe choice.
TL;DR
At APSARD 2026, experts presented reassuring safety data supporting ADHD medication continuation during pregnancy when needed for daily functioning.
Dr. Allison Baker from Massachusetts General Hospital advocated a risk-risk analysis approach rather than automatic discontinuation.
A 2024 meta-analysis found no increased risk of congenital anomalies or miscarriage with methylphenidate or atomoxetine exposure.
The postpartum period requires special attention for mood and focus challenges, with collaborative care recommended.
Shared decision-making with multiple providers—ideally before conception—leads to better outcomes for women and families.
Experts Present Reassuring Safety Data at APSARD Conference
At the APSARD 2026 Annual Conference in San Diego, Dr. Allison S. Baker, a child, adolescent, and perinatal psychiatrist at Massachusetts General Hospital, presented a risk-risk framework for ADHD treatment during pregnancy. Rather than automatically discontinuing medication, Baker advocated for balancing the theoretical risks of medication exposure against the known risks of not supporting focus and attention needs during pregnancy.
“If ADHD pharmacotherapy is required for daily functioning of an individual, it is appropriate to consider and continue in pregnancy,” Baker explained, noting that these discussions should ideally occur “well in advance of pregnancy.” The conference highlighted that ADHD characteristics persist into adulthood in approximately 3% of women—roughly 1 in 30—and many receive their diagnosis during their childbearing years.
The safety data supporting Baker’s recommendations comes from multiple recent studies. A 2024 meta-analysis from the University of Milano-Bicocca found no significantly increased risk of congenital anomalies associated with exposure to methylphenidate or atomoxetine during pregnancy. Similarly, no difference in miscarriage risk was found between women who continued medication and those who did not.
Understanding how dopamine regulation affects focus and daily functioning helps explain why maintaining treatment can be important. Research on dopamine and attention shows that focus abilities depend heavily on brain chemistry—and disrupting that balance can affect everything from driving safety to managing household demands. For women building their families while also building their focus skills, these findings offer important reassurance.
Author Quote"
If ADHD pharmacotherapy is required for daily functioning of an individual, it is appropriate to consider and continue in pregnancy
"
The Postpartum Period Requires Special Attention
Baker emphasized that the focus conversation shouldn’t end at delivery. The postpartum period carries “significant risk for roughening of those comorbid mood and anxiety vulnerabilities,” driven by hormonal transitions, sleep disruption, and increased executive functioning demands. Women rarely experience attention regulation challenges in isolation—mood and anxiety concerns are “the rule, not the exception.”
This highlights why women who are developing their focus skills benefit from comprehensive support. Baker recommended combining pharmacotherapy with non-pharmacologic approaches including psychotherapy, coaching, and mindfulness-based strategies, particularly for moderate to severe attention challenges. The goal isn’t just managing pregnancy—it’s supporting the whole person through a major life transition.
Key Takeaways:
1
Reassuring safety data for many: A 2024 meta-analysis found no significantly increased risk of congenital anomalies or miscarriage associated with common ADHD medications during pregnancy.
2
Risk-risk framework shifts the conversation: Experts now recommend weighing medication risks against the known risks of not treating attention challenges, including driving safety and daily functioning impacts.
3
Postpartum support is essential: The postpartum period brings additional challenges for focus and mood regulation, requiring ongoing collaborative care from multiple providers.
Shared Decision-Making Leads to Better Outcomes
Perhaps the most empowering aspect of Baker’s presentation was her emphasis on collaborative care. She stressed involving pediatrics, obstetrics/gynecology, and psychotherapists in treatment planning, with “shared decision analysis” conversations held well before conception. This approach positions women as active participants in their care rather than passive recipients of one-size-fits-all protocols.
The National Pregnancy Registry for ADHD Medications continues to collect data on these questions, and researchers are studying both medication outcomes and the mental health impacts on families navigating these decisions. What’s becoming clear is that the old binary—medication or no medication—is giving way to more nuanced, individualized approaches that respect each woman’s unique circumstances and daily functioning needs.
Author Quote"
Women rarely have just one silo of ADHD symptoms and nothing else—comorbid mood and anxiety disorders represent the rule, not the exception
"
Every parent deserves the support they need to show up fully for their family—and that includes expectant mothers who are building their focus skills. For too long, women have been caught between outdated protocols that treated medication as an all-or-nothing proposition and fears that prioritizing their own functioning somehow meant failing their baby. This new research reminds us that brains are remarkably capable of growth and change, and that supporting a mother’s attention regulation needs can be an act of care for the whole family. If you’re ready to build focus skills using evidence-based approaches that work with your brain’s natural ability to strengthen attention, the Learning Success All Access Program offers a free trial that includes a personalized Action Plan—and you keep that plan even if you decide it’s not the right fit.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
